Xudong Tang and his team developed ROS-responsive nanoparticles carrying the Fc-fused PD-L1 (programmed cell death-ligand) to enhance the targeted drug delivery and efficacy of PD-L1 pathway-based therapies for IBD (Tang et al., 2024). The gene discussed is CD274; the disease is inflammatory bowel disease.